Primary cytoreductive surgery and adjuvant hormone therapy in women with advanced low-grade serous carcinoma: Reducing overtreatment without compromising survival?

Trial ID # Retrospective Study: Adjuvant Hormone Therapy in LGSC
Phase Two sites
Drug Class Hormonal Therapy: Aromatase
Drug Name Letrozole
Alternate Drug Names Femara
Drugs in Trial Anastrozole, Letrozole, Tamoxifen
Eligible Participant

Stage II-IV low grade serous ovarian cancer

Patients Enrolled

27; 85% optimally debulked, 96% HR+, 32% PR+

Therapy Setting

First-line

Study Design

Open-Label, Non-randomized

Endpoints

PFS, OS, evaluated per RECIST

Efficacy

Surgery+adjuvant hormone therapy:

PFS: Not Reached (41 months follow up)
OS: Not Reached (41 months follow up)

2 year PFS and OS: 82.8% and 96.3%
3 year PFS and OS: 79.0% and 92.6%

Conclusion

Promising PFS and OS in Low Grade Serous Cancer patients treated with hormone therapy following cytoreductive surgery

Reference

Fader AN et al. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival? Gynecol Oncol (2017) 147: 85-91
https://www.ncbi.nlm.nih.gov/pubmed/28768570